Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BeBetter MedSHSE:688759 -2.33%4 Buyback Yield % is 0.00 as of Jul. 28, 2026. GuruFocus rates SHSE:688759 with a GF Score™ of 4/100. Among 736 Biotechnology companies, BeBetter Med ranks worse than 135869.43% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for BeBetter Med's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688759 vs VRTX, REGN, RVMD: Buyback Yield % Comparison
For the Biotechnology subindustry, BeBetter Med's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BeBetter Med Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BeBetter Med's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where BeBetter Med's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BeBetter Med (SHSE:688759) has a Buyback Yield % of 0.00 as of Jul. 28, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on BeBetter Med and its competitors. According to the industry distribution chart, BeBetter Med ranks #999999 out of 736 companies in the Biotechnology industry.
Is BeBetter Med's Buyback Yield % too high?
BeBetter Med's current Buyback Yield % is 0.00. Based on the distribution chart, BeBetter Med ranks #999999 out of 736 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, BeBetter Med has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does BeBetter Med's Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BeBetter Med ranks #999999 out of 736 companies for Buyback Yield %. This places BeBetter Med in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on BeBetter Med and its competitors. BeBetter Med's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BeBetter Med stock overvalued right now?
BeBetter Med (SHSE:688759) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. BeBetter Med's overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For BeBetter Med (SHSE:688759), the current Buyback Yield % is 0.00 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BeBetter Med Inc is a biopharmaceutical company based in China, focusing on independent research and development of drugs. The company focuses on developing novel medicines for treating cancers, autoimmune diseases, and other severe conditions. Key products include the PI3K/HDAC dual inhibitor BEBT-908 and multiple drugs in clinical trial phases targeting cancers. It's a United States subsidiary BeBetter Pharma specializes in next-generation siRNA therapeutics using proprietary delivery platforms aimed at complex diseases like kidney disorders, metabolic and liver diseases, and neurodegenerative conditions. Its pipeline includes oral and injectable drug candidates, some in late-stage trials, and aims to address unmet medical needs through novel mechanisms.
4GF Score
Get the complete analysis for SHSE:688759
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688759 has been successfully added to your 
